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Background: Anemia is the most frequent hematological complica-
tion of lung cancer, particularly in advanced stages. The efﬁcacy of 
epoetin beta (E) is well documented in clinical trials in cancer patients 
(pts) with chemotherapy-induced anemia. This study was conducted to 
assess E use, efﬁcacy, safety and effect on quality of life in cancer pts, 
in usual practice. 
Methods: This prospective, multicenter, longitudinal, observational 
French study assessed a 4-month follow-up of informed pts with solid 
tumor or non myeloid hematological cancer treated with E for chemo-
therapy-related anemia. Data were collected between January 2005 and 
March 2006. Here we focus speciﬁcally on the subgroup of patients 
with lung cancer.
Results: Among 3200 pts enrolled by 423 specialists, 2810 were 
analysed. The most frequent cancer type was lung cancer with 622 pts 
(22% of all pts). Lung cancer pts’ characteristics were: mean age 63±10 
yrs, male 75%, performance status 0 (11%), 1 (48%), ≥2 (41%). TNM 
stages Ia-IIb: 7%, IIIa: 13%, IIIb: 17% and IV: 64%. The median time 
from disease diagnosis to inclusion was 2.7 months. 19% of pts were 
in relapse (median time to relapse: 2 months). 79% of H pts received 
platinum based regimen. 40% of pts received at least one cycle of 
chemotherapy before inclusion. 23% of pts received an anterior 
radiotherapy and 13% of pts had an associated radiotherapy with ongo-
ing chemotherapy. At inclusion, the mean of hemoglobin level was 
10.1±1.1 g/dl and 79% of pts had Hb level < 11 g/dl.
At initiation, pts received a median dose of 30000 U/week of E on a 
once weekly regimen schedule for 96% of pts. E was associated with 
iron supplementation in 62% of pts, and with blood transfusion in 4% 
pts.
Conclusion: These preliminary results describe baseline characteristics 
of lung cancer patients treated with epoetin beta. Final analyses includ-
ing hemoglobin and quality of life evolution under E treatment will be 
presented. In addition, predictive factors of response to E treatment will 
be analyzed.
P1-253 Supportive Care/QOL Posters, Mon, Sept 3 
Quality of life (QOL) evaluation for advanced non-small cell 
lung cancer (NSCLC): a comparison between vinorelbine and 
gemcitabine followed by docetaxel (VGD) versus paclitaxel and 
carboplatin (PC) regimen on a phase III protocol JMTO LC00-03 
(BRI LC03-01)
Kawahara, Masaaki1 Tokoro, Akihiro1 Tada, Harue2 Ishiwata, Ryota3 
Teramukai, Satoshi2 Fukushima, Masanori2 Kubota, Kaoru4 Shinkai, 
Tetsu5 Furuse, Kiyoyuki6 
1 NHO Kinki-chuo Chest Medical Center, Sakai, Japan 2 Translational 
Research Center, Kyoto University, Kyoto, Japan 3 Translational 
Research Informatics Center, Kobe, Japan 4 National Cancer Center 
Hospital East, Matsudo, Japan 5 National Shikoku Cancer Center, Mat-
suyama, Japan 6 Japan Multinational Trial Oragnization, Kyoto, Japan 
Background: JMTO LC00-03, a randomized trial of VGD versus PC 
in patients with advanced NSCLC (2001-2005), showed differences 
between the two treatment groups in response rate (25 vs 37.1%) and 
regimens speciﬁc toxicities including taxane-related toxicities such 
as numbness (0 vs 16.2%) and neuropathy (0.5 vs 9.6%), but not in 
overall survival (MST: 13.6 vs 14.1 mos) and progression-free survival 
(MST: 5.5 vs 5.8 mos). (Kawahara et al, # 7013, ASCO, 2006).
Methods: Patients with advanced NSCLC who were randomly as-
signed to VGD or PC (JMTO LC00-03) were asked to enter this QOL 
study since 2004. After the informed consent, the patients themselves 
assessed Functional Assessment of Cancer Therapy- FACT-L, FACT-
Taxane and FACIT-SP score in baseline, and at 6-, 12-, 18-weeks after 
the treatment. The assessment results were not informed to the partici-
pating physicians. The primary endpoint was the comparison of total 
score of QOL in each assessment between the 2 arms. The longitudinal 
analysis was used to compare mean changes of the QOL score over the 
two treatment groups. 
Results: Eighty-four patients entered this study. Sixty-eight patients 
from the trial (VGD: 34, PC: 34) who submitted both baseline ques-
tionnaire and at least one questionnaire over the course of the treatment 
were eligible. The longitudinal analysis showed signiﬁcant difference 
in the mean score of FACT-Taxane (p<0.001) in the treatment over 
time, but no signiﬁcant differences in the FACT-L score (p=0.261) and 
FACIT-SP (p=0.207). 
Conclusions: There were no statistically signiﬁcant differences in 
FACT-L and FACIT-SP score between the two groups. However, there 
was a signiﬁcant difference in FACT-Taxane score favoring VGD. This 
may be due to the difference in frequency of neuropathy with docetaxel 
than with paclitaxel.
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Background: About 30-40% of lung cancer patients have skeletal me-
tastasis and about half of them experience skeletal related events(SREs; 
bone pain, spinal cord compression, pathologic fracture, radiation 
therapy to bone, bone surgery). Zoledronic acid has potent anti-resorp-
tive properties on bone metabolism. In addition, it has an anti-neoplas-
tic effect on cancer cell. In a randomized controlled trial, zoledronic 
acid reduced the incidence of SREs and delayed the time to ﬁrst SRE in 
patients with skeletal metastasis from lung and other solid tumors. 
Methods: From October 2003, 132 lung cancer patients with bone 
metastasis have been observed for the incidence of SREs and time to 
ﬁrst SRE. Fifty-two patients (Treatment group, TG) were treated with 
zoledronic acid (4mg 3weekly) and the remaining 80 patients (Control 
group, CG) did not receive zoledronic acid. 
Results: Treatment of zoledronic acid ranged from 1 to 13 cycles 
(mean=9.5 cycles). Fifty-three(40.2%) patients experienced SREs; ra-
diation therapy(33), spinal cord compression(4), pathologic fracture(6), 
bone surgery(2), bone pain(15). The incidence of SREs was not sig-
niﬁcantly different between TG(32.7% 17/52) and CG(45.0%, 36/80, 
p=0.2). Median time to ﬁrst SRE was 289 days (95% CI; 152~426 
days) in 132 patients, and no signiﬁcant difference between the two 
groups was observed. 
